• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%

    6/10/26 4:05:00 PM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email

    LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it has entered into Incremental Amendment No. 3 (the "Third Amendment") to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the "Existing Credit Agreement" and, as amended by the Third Amendment, the "Credit Agreement").

    Pursuant to the Third Amendment, certain term lenders under the Credit Agreement funded RadNet an incremental term loan in the aggregate principal amount of $250.0 million (the "2026 Incremental Term Loan"), which was added to and forms a part of the existing term loan under the Credit Agreement (the "Existing Term Loan," together with the 2026 Incremental Term Loan, the "Term Loan"). The 2026 Incremental Term Loan will mature on April 18, 2031—coincident with the maturity date of the $958.7 million balance of the Existing Term Loan under the Existing Credit Agreement. Quarterly payments of principal on the Term Loan will be approximately $3.1 million compared to approximately $2.4 million prior to the entry of the Third Amendment.   The proceeds of the 2026 Incremental Term Loan are expected to be used to finance future acquisitions, organic expansion initiatives, health system partnerships and for other general corporate purposes.

    In addition, with the successful completion of the Third Amendment, the interest rate on the Term Loan was reduced by 0.25% to, at RadNet's election, either Term SOFR plus 2.00% or the alternate base rate plus 1.00%. In addition, the interest rate on RadNet's existing $282 million revolving credit facility (currently undrawn upon) was reduced by 0.25%.   In connection with the Third Amendment, RadNet has provided call protection to the term loan lenders participating in the repricing of the Existing Term Loan for a period of six months following the Third Amendment.  

    Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, commented, "We appreciate the continued support of Barclays and our other relationship banks and term loan lenders. This amendment provides us with additional flexibility to pursue strategic growth opportunities across RadNet's national imaging center network and technology platforms, while reducing the interest rate on our credit facilities. The proceeds of approximately $250 million adds to the $455 million cash balance as of March 31, 2026, positioning us to advance our growth strategy and create long-term value for our stockholders." 

    This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of RadNet and shall not constitute an offer, solicitation or sale in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration and qualification under the securities laws of such state or jurisdiction.

    About RadNet, Inc.

    RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet's imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under its DeepHealth brand and teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at radnet.com.



    Forward Looking Statements 

    This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of RadNet's current beliefs, expectations and assumptions regarding the future of RadNet's business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements in this press release include, among others, statements RadNet makes regarding its expected use of proceeds from the 2026 Incremental Term Loan and its ability and success in pursuing strategic growth opportunities.

    Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet's control, which may cause actual events to be materially different from those expressed or implied herein. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could impact RadNet's expected use of proceeds from the 2026 Incremental Term Loan and its ability and success in pursuing strategic growth opportunities include, among others, the following:

    • a decline or anticipated decline in RadNet's operating results or financial position, as a result of operational issues, regulatory changes, litigation, casualty loss, or other factors;
    • changes in general economic conditions nationally and regionally in the markets in which RadNet operates;
    • volatility in interest and exchange rates, or credit markets;
    • the occurrence of hostilities, political instability or catastrophic events; and
    • the emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases.



    Any forward-looking statement contained in this press release is based on information currently available to RadNet and speaks only as of the date on which it is made. RadNet undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that it may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.

    Contact:

    RadNet, Inc.

    Mark Stolper, 310-445-2800

    Executive Vice President and Chief Financial Officer



    Primary Logo

    Get the next $RDNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    1/9/2026$92.00Overweight
    KeyBanc Capital Markets
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Swartz David L sold $145,449 worth of shares (2,699 units at $53.89), decreasing direct ownership by 2% to 177,013 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/22/26 4:15:18 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Pres & CEO, Digital Health Wesdorp Cornelis sold $276,022 worth of shares (4,750 units at $58.11), decreasing direct ownership by 6% to 69,075 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/18/26 6:03:03 PM ET
    $RDNT
    Medical Specialities
    Health Care

    President, CEO Berger Howard G gifted 90 shares (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/18/26 6:00:23 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    SEC Filings

    View All

    RadNet Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    6/10/26 5:23:08 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - RadNet, Inc. (0000790526) (Filer)

    6/3/26 9:08:18 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    6/3/26 8:07:02 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on RadNet with a new price target

    KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00

    1/9/26 9:07:04 AM ET
    $RDNT
    Medical Specialities
    Health Care

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Raymond James with a new price target

    Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

    3/5/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%

    LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it has entered into Incremental Amendment No. 3 (the "Third Amendment") to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the "Existing Credit Agreement" and, as amended by the Third Amendment, the "Credit Agreement"). Pursuant to the Third Amendment, certain term lenders under the Credit Agreement funded RadNet an incremental t

    6/10/26 4:05:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting

    SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) --  DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today announced the launch of Reporting Pro, a next-generation AI-powered solution designed to transform the way radiologists generate clinical reports and findings for their referring physicians. Reporting Pro was introduced at RSNA 2025 and is now available for commercial deployment. Reporting Pro includes capabilities that bring speech recognition, AI-generated clinical findings, measurements, AI-generated impressions, quality assurance and structured reporting into one seamless workflow. "Radiology is ent

    6/10/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities

    LOS ANGELES, June 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it seeks to secure an incremental term loan in the aggregate principal amount of $200 million (the "Proposed 2026 Incremental Term Loan") pursuant to a proposed amendment (the "Proposed Amendment") to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the "Existing Credit Agreement" and, the transaction, the "Loan Transaction"). If

    6/3/26 8:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

    Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

    9/12/24 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Financials

    Live finance-specific insights

    View All

    RadNet Reports Record First Quarter Financial Results and Revises Upwards 2026 Imaging Center Financial Guidance Ranges for Revenue, Adjusted EBITDA and Free Cash Flow

    Total Company Revenue increased 22.1% to $575.6 million in the first quarter of 2026 from $471.4 million in the first quarter of 2025Revenue from the Digital Health reportable segment increased 51.5% to $29.1 million in the first quarter of 2026 from $19.2 million in the first quarter of 2025; Annual Recurring Revenue(4) (ARR) increased from $49.8 million at March 31, 2025 to $96.9 million at March 31, 2026Total Company Adjusted EBITDA(1) was $63.3 million in the first quarter of 2026 as compared with $46.4 million in the first quarter of 2025, an increase of 36.3%; Digital Health reportable segment Adjusted EBITDA(1) decreased to $1.3 million in the first quarter of 2026 from $3.7 million i

    5/10/26 4:05:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Announces Date of its First Quarter 2026 Financial Results Conference Call

    LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it will host a conference call to discuss its first quarter 2026 financial results on Monday, May 11, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-744-1280. International callers can dial 412-564-6465. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1761306&tp_key=ea5d61284c. An archived replay of the call will also be available

    4/28/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

    LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr

    3/4/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care